Place of Origin: | China |
Brand Name: | RAWSGEAR |
Certification: | USP, HPLC |
Model Number: | 317318-84-6 |
Minimum Order Quantity: | 10g |
---|---|
Price: | Negotiable |
Packaging Details: | Foil bag |
Delivery Time: | 3-5 work days |
Payment Terms: | T/T, Western Union, MoneyGram, Bitcoins |
Supply Ability: | Mass in stock |
Product Name: | GW 0742 | Alias: | GW 610742, GW-0742 |
---|---|---|---|
MF: | C21H17F4NO3S2 | Grade: | Pharmaceutical Grade |
Dosage: | 20-30mg Per Day | Purity: | 99.50% |
China Raw Material Strong Leavening Sugar GW0742 Powder For Obesity Treatment 317318-84-6
GW0742 Basic Info:
Product Name | GW 0742 |
Alias | GW 610742, GW-0742 |
CAS | 317318-84-6 |
MF | C21H17F4NO3S2 |
Purity | 99.50% |
Dosage | 20-30mg per day |
Grade | Pharmaceutical Grade |
Appearance | White powder |
GW0742 / GW610742 Description:
GW0742, also known as GW610742, is a PPARδ/β agonist. GW0742 Induces Early Neuronal Maturation of Cortical Post-Mitotic Neurons. GW0742 prevents hypertension, vascular inflammatory and oxidative status, and endothelial dysfunction in diet-induced obesity. GW0742 has direct protective effects on right heart hypertrophy.GW0742 may enhance lipid metabolism in heart both in vivo and in vitro.
GW0742 (GW610742) is a potent and highly selective PPARδ agonist. EC50 values are 1nM, 1.1μM and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively. IC50 value: 1nM, 1.1μM and 2 μM (EC50, for PPARδ, -α, and -γ) Target: PPAR in vivo: GW0742 is a synthetic high affinity PPAR β/δ agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis. Data showed that GW0742-treatment (0.3 mg/Kg, 10 percent DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of:
1) cytokine production;
2) leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity;
3) IkBα degradation and NF-kB nuclear translocation;
4) ERK phosphorylation;
5) stress oxidative by NO formation due to iNOS expression;
6) nitrotyrosine and PAR localization;
7) the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, our results clearly show that GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO--instillation in mice.
GW0742 Application:
GW 0742 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue , and GW 501516 has been demonstrated to reverse metabolic abnormalities in obese men with pre-diabetic metabolic syndrome , most likely by stimulating fatty acid oxidation .
GW0742 has been proposed as a potential treatment for obesity and related conditions , especially when used in conjunction with a synergistic compound AICAR , as the combination has been shown to significantly increase exercise endurance in human.
How GW0742 Works:
The highest antagonist activity for GW0742 was found for VDR and the androgen receptor (AR). Surprisingly, GW0742 behaved as PPAR agonist/antagonist activating transcription at lower concentration and inhibiting this effect at higher concentrations. A unique spectroscopic property of GW0742 was identified as well. In the presence of rhodamine-derived molecules, GW0742+ increased fluorescence intensity and fluorescence polarization at an excitation wavelength of 595 nm and emission wavelength of 615 nm in a dose dependent manner.
The GW0742-inhibited NR-coactivator binding resulted in a reduced expression of five different NR target genes in LNCaP cells in the presence of agonist. Especially VDR target genes CYP24A1, IGFBP-3 and TRPV6 were negatively regulated by GW0742. GW0742 is the first VDR ligand inhibitor lacking the secosteroid structure of VDR ligand antagonists. Nevertheless, the VDR-meditated downstream process of cell differentiation was antagonized by GW0742 in HL-60 cells that were pretreated with the endogenous VDR agonist 1,25-dihydroxyvitamin D3.
GW0742 / GW610742 Biological Activity:
GW0742 / GW610742 is a potent and highly selective PPARδ agonist. EC50 values are 1nM, 1.1μM and 2 μM for transactivation of human PPARδ, -α, and -γ receptors respectively.
GW0742 is a synthetic high affinity PPAR β/δ agonist, and its possible role in preventing the advance of inflammatory and apoptotic processes induced by bleomycin, that long-term leads to the appearance of pulmonary fibrosis. Our data showed that GW0742-treatment (0.3 mg/Kg, 10 percent DMSO, i.p.) has therapeutic effects on pulmonary damage, decreasing many inflammatory and apoptotic parameters detected by measurement of:cytokine production; leukocyte accumulation, indirectly measured as decrease of myeloperoxidase (MPO) activity; IkBα degradation and NF-kB nuclear translocation; ERK phosphorylation; stress oxidative by NO formation due to iNOS expression; nitrotyrosine and PAR localization; the degree of apoptosis, evaluated by Bax and Bcl-2 balance, FAS ligand expression and TUNEL staining. Taken together, our results clearly show that GW0742 reduces the lung injury and inflammation due to the intratracheal BLEO--instillation in mice.
Related Products:
MK-2866 | CAS:1202044-20-9,841205-47-8 |
LGD-4033 | CAS:1165910-22-4 |
GW-501516 | CAS:317318-70-0 |
MK-677 | CAS:159752-10-0 |
GTX-007/S4/Andarine | CAS:401900-40-1 |
SR-9009 | CAS:1379686-30-2 |
RAD-140 | CAS:118237-47-0 |
YK-11 | CAS:431579-34-9 |
GW0742 | CAS:317318-84-6 |
AICAR | CAS:2627-69-2 |
GS5816 | CAS:1377049-84-7 |
Contact Person: Miss. Gayle
Tel: +8615711952876
Fax: 86--15711952876